PP
NKTR icon

Paloma Partners’s Nektar Therapeutics NKTR Stock Holding History

Paloma Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,682
Closed -$68.5K – 1514
2024
Q2 		$68.5K Buy
+3,682
New +$77.6K ﹤0.01% 1121
2020
Q1 		– Sell
-12,436
Closed -$4.03M – 1796
2019
Q4 		$4.03M Buy
12,436
+4,936
+66% +$1.43M 0.06% 309
2019
Q3 		$2.05M Buy
+7,500
New +$2.75M 0.04% 419
2018
Q4 		– Sell
-1,968
Closed -$1.8M – 1625
2018
Q3 		$1.8M Sell
1,968
-25,719
-93% -$22M 0.03% 496
2018
Q2 		$20.3M Buy
27,687
+27,545
+19,398% +$31.8M 0.37% 30
2018
Q1 		$227K Sell
142
-725
-84% -$934K ﹤0.01% 1751
2017
Q4 		$777K Buy
+867
New +$513K 0.01% 1157
2016
Q3 		– Sell
-1,041
Closed -$222K – 2031
2016
Q2 		$222K Buy
+1,041
New +$233K ﹤0.01% 1907
2015
Q3 		– Sell
-2,939
Closed -$551K – 1804
2015
Q2 		$551K Buy
+2,939
New +$506K 0.01% 1037
2015
Q1 		– Sell
-1,006
Closed -$234K – 1347
2014
Q4 		$234K Sell
1,006
-994
-50% -$212K 0.01% 954
2014
Q3 		$362K Buy
+2,000
New +$383K 0.02% 652
2013
Q4 		– Sell
-667
Closed -$105K – 1138
2013
Q3 		$105K Buy
+667
New +$123K ﹤0.01% 846

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Paloma Partners's NKTR Position: Q3 2024 in Review

Paloma Partners sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 3,682 shares — an estimated $68.5K sold.

Paloma Partners first reported a position in NKTR in Q3 2013 and held it in 12 quarters. The position peaked at $20.3M in Q2 2018. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

  • Paloma Partners reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 3,682 Nektar Therapeutics shares in Q3 2024, an estimated $68.5K.
  • Paloma Partners first reported a position in Nektar Therapeutics in Q3 2013 and held it in 12 quarters.
  • Paloma Partners's Nektar Therapeutics position peaked at $20.3M in Q2 2018.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.